Lupin Appoints New Compliance Manager As More Deficiencies Found
Diana Amador-Toro Takes Lead As FDA Issues Observations Over Tarapur Site
Lupin has named a new head of compliance, emphasizing the importance of achieving the highest quality standards just weeks after the FDA notified the firm of observations following an inspection at its Indian facility in Tarapur.
You may also be interested in...
Lupin’s 2021/22 financial year results revealed weakness in its core US generics business amid challenging market conditions. The Indian firm will continue to throw its weight behind its domestic business while rebuilding the US operation with more complex, high-value launches.
Formycon has become the latest firm to announce a new CEO, after similar moves at Orion and Strides. Meanwhile, Gedeon Richter has made management changes and a new director has joined Coherus.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.